ArchiMed to acquire a majority stake in Suanfarma from Intermediate Capital Group.

ArchiMed, an investment firm, agreed to acquire a majority stake in Suanfarma, a manufacturer and distributor of active pharmaceutical and nutraceutical ingredients, from Intermediate Capital Group, an alternative asset manager. Financial terms are not disclosed. “Given the increasing outsourcing of API and nutraceutical services, the new strategic need for better global supply chain control and an exceptional number of complex ingredients coming off patent, we see fantastic opportunities for manufacturing and distribution excellence in this sector. Suanfarma’s management has the experience to manage an aggressive consolidation of the fast-growing markets for APIs and nutraceuticals. They’ve also got that rare level of expertise and industry intelligence to develop a full suite of complex APIs and nutraceuticals at a time when leading pharma companies are looking for one-stop shopping,” André-Michel Ballester, ArchiMed Managing Partner.